{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:26Z","timestamp":1793640746346,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS-90634"],"award-info":[{"award-number":["NS-90634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS-131416"],"award-info":[{"award-number":["NS-131416"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR-70517"],"award-info":[{"award-number":["AR-70517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR-81018"],"award-info":[{"award-number":["AR-81018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-177600"],"award-info":[{"award-number":["AI-177600"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymthe.2023.10.015","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:45:55Z","timestamp":1696945555000},"page":"3123-3126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":262,"title":["Lethal immunotoxicity in high-dose systemic AAV therapy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-1132","authenticated-orcid":false,"given":"Dongsheng","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.10.015_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2016.07.006","article-title":"Systemic delivery of adeno-associated viral vectors","volume":"21","author":"Duan","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2023.10.015_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-023-02685-w","article-title":"Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey","author":"Toro","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","article-title":"FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2023.10.015_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy\" by Wilson and Flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1089\/hum.2021.29182.bfs","article-title":"Fourth Boy Dies in Clinical Trial of Astellas' AT132","volume":"32","author":"Philippidis","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib7","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2023.10.015_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Transfer Therapy","volume":"10","author":"Lek","year":"2023","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2023.10.015_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","article-title":"After Patient Death, FDA Places Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Trial","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.10.015_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2023.10.015_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kint.2016.11.029","article-title":"Capillary leak syndrome: etiologies, pathophysiology, and management","volume":"92","author":"Siddall","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2023.10.015_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/asheducation-2013.1.605","article-title":"Hemophagocytic lymphohistiocytosis: pathogenesis and treatment","volume":"2013","author":"Janka","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2023.10.015_bib14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"Galletta","year":"2022","journal-title":"J.\u00a0Clin. Pharm. Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib15","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.10.015_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1620\/tjem.140.381","article-title":"Endothelial alterations of skeletal muscle capillaries in childhood myopathies","volume":"140","author":"Kobayashi","year":"1983","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.ymthe.2023.10.015_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/path.5704","article-title":"Dystrophin deficiency impairs vascular structure and function in the canine model of Duchenne muscular dystrophy","volume":"254","author":"Kodippili","year":"2021","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ymthe.2023.10.015_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib19","article-title":"An Overview of Nonclinical and Clinical Liver Toxicity Associated With AAV Gene Therapy","volume":"1926233231201408","author":"Whiteley","year":"2023","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ymthe.2023.10.015_bib20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity - 'one and done' or 'slower and lower'?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.10.015_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/ckj\/sfz040","article-title":"An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy","volume":"12","author":"Aigner","year":"2019","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymthe.2023.10.015_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hum.2023.056","article-title":"Immune responses to muscle-directed AAV gene transfer in clinical trials","volume":"34","author":"Kumar","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib24","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.10.015_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41434-023-00401-5","article-title":"Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings","volume":"30","author":"Chand","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2023.10.015_bib27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/hum.2023.057","article-title":"Progress in bioengineering of myotropic Adeno-associated viral (AAV) gene therapy vectors","volume":"34","author":"Liu","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/hum.2023.29242.ddu","article-title":"Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond","volume":"34","author":"Duan","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.015_bib29","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623005567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623005567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:06:17Z","timestamp":1778616377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623005567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1525001623005567"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.10.015","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lethal immunotoxicity in high-dose systemic AAV therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}